Amedisys, Inc. (NASDAQ:AMED) Receives $100.75 Average Target Price from Brokerages

Amedisys, Inc. (NASDAQ:AMED) has been given an average rating of “Hold” by the five brokerages that are currently covering the firm, MarketBeat.com reports. Four analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The average twelve-month price target among brokers that have covered the stock in the last year is $100.75.

A number of analysts recently weighed in on the stock. Royal Bank of Canada restated an “outperform” rating and set a $100.00 target price on shares of Amedisys in a research note on Wednesday, April 16th. Stephens reissued an “equal weight” rating and issued a $101.00 target price on shares of Amedisys in a research report on Tuesday, March 4th.

Hedge Funds Weigh In On Amedisys

Several institutional investors have recently bought and sold shares of AMED. Barclays PLC raised its position in Amedisys by 49.5% in the third quarter. Barclays PLC now owns 15,529 shares of the health services provider’s stock worth $1,500,000 after acquiring an additional 5,142 shares in the last quarter. Geode Capital Management LLC increased its position in Amedisys by 1.3% during the third quarter. Geode Capital Management LLC now owns 567,105 shares of the health services provider’s stock worth $54,746,000 after buying an additional 7,071 shares in the last quarter. Oddo BHF Asset Management Sas purchased a new stake in Amedisys during the 3rd quarter worth about $7,238,000. Versant Capital Management Inc raised its position in shares of Amedisys by 68.5% in the fourth quarter. Versant Capital Management Inc now owns 450 shares of the health services provider’s stock valued at $41,000 after buying an additional 183 shares during the last quarter. Finally, HBW Advisory Services LLC acquired a new position in Amedisys in the 4th quarter valued at $38,000. 94.36% of the stock is owned by institutional investors and hedge funds.

Amedisys Stock Performance

NASDAQ:AMED opened at $91.76 on Wednesday. Amedisys has a fifty-two week low of $82.15 and a fifty-two week high of $98.95. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.19 and a current ratio of 1.19. The company has a 50 day moving average price of $92.14 and a 200 day moving average price of $91.86. The stock has a market capitalization of $3.01 billion, a P/E ratio of 36.41, a PEG ratio of 1.78 and a beta of 0.89.

Amedisys (NASDAQ:AMED) last announced its quarterly earnings data on Wednesday, February 26th. The health services provider reported $0.96 earnings per share for the quarter, missing analysts’ consensus estimates of $1.05 by ($0.09). The business had revenue of $598.05 million during the quarter, compared to analyst estimates of $602.38 million. Amedisys had a net margin of 3.57% and a return on equity of 12.20%. Equities research analysts forecast that Amedisys will post 4.4 EPS for the current year.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.